RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.51%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$791M
AUM Growth
+$791M
(-9.1%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-9.51%
Top 10 Holdings %
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15
Top Buys
| 1 |
Danaher
DHR
|
$15.7M |
| 2 |
Eli Lilly
LLY
|
$12.6M |
| 3 |
Encompass Health
EHC
|
$12.1M |
| 4 |
Cardinal Health
CAH
|
$9.24M |
| 5 |
Neurocrine Biosciences
NBIX
|
$7.47M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$19.8M |
| 2 |
Oscar Health
OSCR
|
$15.2M |
| 3 |
Procept Biorobotics
PRCT
|
$14.9M |
| 4 |
UnitedHealth
UNH
|
$14.7M |
| 5 |
McKesson
MCK
|
$14.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cooper Companies
COO
$13.4B
| $12.1M | 1.53% | 170,000 -66,000 | -28% | -$4.7M |
|
27
Jazz Pharmaceuticals
JAZZ
$7.75B
| $11.6M | 1.46% | 109,030 -15,270 | -12% | -$1.62M |
|
28
HCA Healthcare
HCA
$94.5B
| $11.4M | 1.44% | 29,778 +13,000 | +77% | +$4.98M |
|
|
29
Procept Biorobotics
PRCT
$2.23B
| $10.9M | 1.38% | 190,000 -258,000 | -58% | -$14.9M |
|
30
Cigna
CI
$80.3B
| $10.6M | 1.34% | 32,000 +3,800 | +13% | +$1.26M |
|
31
Akero Therapeutics
AKRO
$3.74B
| $10.5M | 1.33% | 197,600 +105,100 | +114% | +$5.61M |
|
|
VRNA
32
Verona Pharma
VRNA
$9.16B
| $10.1M | 1.27% | 106,500 +36,500 | +52% | +$3.45M |
|
33
Natera
NTRA
$23.1B
| $9.71M | 1.23% | 57,500 -81,000 | -58% | -$13.7M |
|
|
34
UnitedHealth
UNH
$281B
| $9.49M | 1.2% | 30,430 -47,000 | -61% | -$14.7M |
|
35
Axsome Therapeutics
AXSM
$6.05B
| $9.48M | 1.2% | 90,800 -18,800 | -17% | -$1.96M |
|
|
36
Cardinal Health
CAH
$35.5B
| $9.24M | 1.17% | +55,000 | New | +$9.24M |
|
37
BioMarin Pharmaceuticals
BMRN
$11.2B
| $8.23M | 1.04% | 149,650 -115,350 | -44% | -$6.34M |
|
38
Abbott
ABT
$231B
| $7.96M | 1.01% | 58,500 +6,500 | +13% | +$884K |
|
39
Ionis Pharmaceuticals
IONS
$6.79B
| $7.19M | 0.91% | 182,000 +101,000 | +125% | +$3.99M |
|
|
40
Oscar Health
OSCR
$4.31B
| $6.69M | 0.85% | 312,092 -710,651 | -69% | -$15.2M |
|
41
Molina Healthcare
MOH
$9.8B
| $6.61M | 0.84% | 22,200 -46,000 | -67% | -$13.7M |
|
42
Merus
MRUS
$4.98B
| $6.1M | 0.77% | 116,000 +41,500 | +56% | +$2.18M |
|
43
Alcon
ALC
$39.5B
| $5.99M | 0.76% | +68,000 | New | +$5.99M |
|
44
Dynavax Technologies
DVAX
$1.19B
| $5.6M | 0.71% | 565,000 | – | – |
|
45
Penumbra
PEN
$10.6B
| $5.52M | 0.7% | 21,500 +19,300 | +877% | +$4.95M |
|
46
Centene
CNC
$14.3B
| $5.41M | 0.68% | 99,757 -26,243 | -21% | -$1.42M |
|
47
Syndax Pharmaceuticals
SNDX
$1.41B
| $5.38M | 0.68% | 574,000 +141,000 | +33% | +$1.32M |
|
48
Bruker
BRKR
$5.16B
| $5.08M | 0.64% | 123,315 +81,000 | +191% | +$3.34M |
|
|
AVR
49
Anteris Technologies Global Corp. Common Stock
AVR
$145M
| $4.74M | 0.6% | 1,250,763 -39,237 | -3% | -$149K |
|
50
Astrana Health
ASTH
$1.48B
| $4.73M | 0.6% | 190,000 +40,000 | +27% | +$995K |
|